AlphAIAlphAI — Financial news for AI agents
investing.comOCT 221 min read$IART

Citizens cuts Integra LifeSciences stock price target on facility flooding

Citizens cut Integra LifeSciences' (IART) price target to $22 from $25, citing Q3 2026 revenue miss and facility flooding. IART stock is down 12.5% weekly. Q3 revenue was $411.2M, slightly below estimates, but EPS beat at $0.59. Flooding impacted Q3 revenue by $7M and may affect Q4 by $15M-$20M.

Original reporting
investing.com
Published Oct 22, 2026, 10:01 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 10:34 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$IART
Bearish
high confidence
Mentioned
$IART
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$IARTBearishHigh
01

Why it matters

The downgrade reflects a material shift in earnings outlook, prompting likely short‑term price decline.

02

Market read

Target reduction and guidance downgrade are fresh, material news for IART, offering a clear trading signal.

03

What to watch

Potential insurance recoveries or cost‑saving measures could mitigate the revenue shortfall.

Relevance 7/10Novelty 8/10Timing: today

Background

Citizens Research downgraded IART after the company's Cincinnati plant flooding reduced Q3 revenue and lowered FY2026 guidance.

Company-level read

Ticker impact

$IARTBearishHigh confidence
Context

Citizens lowered its price target on Integra LifeSciences (IART) to $22 citing flooding‑related revenue hit and reduced FY2026 guidance.

Expected impact

downward pressure as investors price in lower guidance and reduced revenue.

Evidence & confidence

Target cuts are immediate actionable signals; the flooding impact is a concrete, material catalyst.

Market effects

Sector

Medical device and biotech firms with similar manufacturing exposure may see heightened risk perception.

Regional

U.S. healthcare sector could face modest downside as analysts reassess supply‑chain risks.

Global

Limited to companies with U.S. listings; no broad macro effect.

Counterpoint

What could challenge this read

If the flood impact is temporary, the stock may be oversold and could rebound on later earnings beats.

Key entities

  • company
    Integra LifeSciences Holdings

    Medical device manufacturer impacted by flooding.

  • analyst
    Citizens Research

    Provided the price‑target cut and rating.

Read at source← All news

Related articles

OCT 22
$IARTMedAI 8/10

IART Q3 deep dive: Cincinnati disruption and Tissue Reconstruction challenges weigh on outlook

Integra LifeSciences (IART) reported Q3 operating margin of 4.6%, down from 9.9% YoY. Management cut full-year Adjusted EPS guidance to $2.35 midpoint, citing Cincinnati facility disruption and Tissue Reconstruction challenges. Neurosurgery growth offset some weaknesses. Debt refinancing improved liquidity, but higher interest expense is expected. Recovery from flood impact anticipated by mid-2027.

finance.yahoo.com2 min
OCT 21
$IARTMed

Integra LifeSciences (IART) Reports Q3 Revenue In Line with Guid

Integra LifeSciences (IART) reported Q3 revenue of $411M, meeting the lower end of its guidance. The company lowered its full-year revenue outlook by $30M due to operational disruptions. IART's P/S ratio is 0.57, below historical and industry averages. The company has a GF Score of 69, indicating mixed fundamentals with strengths in momentum and profitability but weaknesses in growth and financial strength. Insider activity shows net buying of $0.1M, while institutional interest is mixed.

gurufocus.com3 min